|
Aug 15
|
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
|
|
Aug 15
|
Financial Services Roundup: Market Talk
|
|
Aug 14
|
'Big Short' investor Burry turned more bullish on second quarter
|
|
Aug 14
|
Students Earn Top Awards at 42nd Annual Research Science Institute at MIT
|
|
Aug 13
|
Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares
|
|
Aug 13
|
5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call
|
|
Aug 13
|
REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges
|
|
Aug 12
|
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
|
|
Aug 12
|
Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810
|
|
Aug 12
|
Sanofi halts Praluent supply in China due to limited availability
|
|
Aug 12
|
Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners
|
|
Aug 11
|
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
|
|
Aug 11
|
Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
|
|
Jul 29
|
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
|
|
Jul 28
|
Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)
|
|
Jul 27
|
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
|
|
Jul 26
|
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal
|
|
Jul 25
|
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
|
Jul 25
|
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
|
|
Jul 25
|
Regeneron Pharmaceuticals Earnings Preview: What to Expect
|